Cabaletta Bio, Inc. (CABA)
Nasdaq: CABA · Biological Products, (No Diagnostic Substances) · Philadelphia, PA · filing with the SEC since 2018
Who owns Cabaletta Bio, Inc.
As filed with the SECHolders of 5% or more
9
T. Rowe Price Investment Management, Inc. holds 11.6% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
12
report now, of 14 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 9 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Aug 14, 2026 · COMMON STOCK · 10.2% in Feb 17, 2026
Prudential Financial, Inc.
SCHEDULE 13G/A · filed Jun 5, 2026 · Common Stock · 8.9% in Nov 7, 2025
Jennison Associates LLC
SCHEDULE 13G/A · filed Jun 4, 2026 · Common Stock · 8.9% in Nov 5, 2025
Bain Capital Life Sciences Opportunities III, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.00001 par value per share · 9.99% in Aug 14, 2025
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 12, 2026 · Common Stock, $0.00001 par value per share · 9.99% in Aug 12, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 5.9% in Jul 27, 2026
Cormorant Asset Management, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.00001 per share · 9.03% in May 15, 2026
Norges Bank
SCHEDULE 13G · filed Aug 12, 2026 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Alyeska Investment Group, L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 6.03% in Nov 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Jul 29, 2025 · Common Stock · reported falling below 5%
Kenneth Griffin
SCHEDULE 13G/A · filed Nov 14, 2025 · Common stock, par value $0.00001 per share (the "Shares") · reported falling below 5%, from 5.2% in Jun 20, 2025
Nichtberger Steven
SCHEDULE 13G/A · filed Aug 11, 2025 · Common Stock, par value $0.00001 per share · reported falling below 5%
Millennium Management LLC
SCHEDULE 13G/A · filed Jul 23, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 5.3% in Feb 18, 2026
What CABA reports owning in othersstakes of 5% or more, and other ties
3 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 23, 2026.
Insider tradesForm 4
0sales
8purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 30 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Nichtberger Steven | President & CEO | 0 | $0 | 0 | 1 | $100,000 |
| Binder Gwendolyn | President, Science & Tech. | 0 | $0 | 0 | 1 | $0 |
| Chang David J. | Chief Medical Officer | 0 | $0 | 0 | 1 | $0 |
| Gavel Steve | Chief Commercial Officer | 0 | $0 | 0 | 1 | $100,000 |
| Gerard Michael | General Counsel | 0 | $0 | 0 | 1 | $0 |
| Bollard Catherine | director | 0 | $0 | 0 | 1 | $0 |
| Simon Mark | director | 0 | $0 | 0 | 1 | $0 |
| Tomasello Shawn | director | 0 | $0 | 0 | 1 | $100,000 |